Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Year Of Change: Viatris Ploughs Ahead With Brand Ambitions

Firm Has Continued To Shift Its Interests Toward Innovative Products

Executive Summary

In 2024, Viatris will initiate the second phase of its long-term business plan, which will see it step away from the perceived volatility of the generics space and begin to move toward innovative and high-growth products. The past year has seen it lay the groundwork for this pivot, shedding surplus business units and making significant hires from the branded space.

You may also be interested in...



Off-Patent Personnel Moves In 2023 Reflect Growing Interest In Innovator Space

Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.

Viatris Picks Brand-Recognized R&D Head To Fuel Novel Ambitions

Viatris CEO Scott Smith is to work alongside an exec from not one but two of his former employers, after Philippe Martin was appointed to head up R&D at the firm and drive its ambitions in the novel space.

Viatris Readies Landmark Botox Biosimilar, Clinical Trial Coming In H1 2024

Viatris has provided the latest on plans to bring a biosimilar to the world-renowned Botox cosmetic and therapeutic brand, while also discussing other opportunities on the slate, including its pipeline of complex injectables.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153186

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel